DownloadHi-Res Photo

Vincent DeVita Jr, MD

Amy and Joseph Perella Professor of Medicine (Medical Oncology) and Professor of Epidemiology (Chronic Diseases)

Research & Publications
Biography
News

Coauthors

Robert Makuch

Selected Publications

DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 11th Edition.DeVita VT, Lawrence TS, Rosenberg SA, (Eds) DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 11th Edition. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2018.
Progress in the Treatment of Hodgkin’s LymphomaLongo DL, DeVita VT. Progress in the Treatment of Hodgkin’s Lymphoma. New England Journal Of Medicine 2017, 378: 392-394. PMID: 29224505, DOI: 10.1056/nejme1715141.
The Death of Cancer: After Fifty Years on the Front Lines of Medicine, a Pioneering Oncologist Reveals Why the War on Cancer is Winnable--and How We Can Get ThereDeVita VT, DeVita-Raeburn E. The Death of Cancer: After Fifty Years on the Front Lines of Medicine, a Pioneering Oncologist Reveals Why the War on Cancer is Winnable--and How We Can Get There. New York, NY, Sarah Crighton Books at Farrar, Straus and Giroux, November 3, 2015.
Clinical cancer research: the past, present and the futureDeVita VT, Eggermont AM, Hellman S, Kerr DJ. Clinical cancer research: the past, present and the future. Nature Reviews Clinical Oncology 2014, 11: 663-669. PMID: 25245981, DOI: 10.1038/nrclinonc.2014.153.
Treatment of Hodgkin Lymphoma: A 50-Year PerspectiveCanellos GP, Rosenberg SA, Friedberg JW, Lister TA, DeVita VT. Treatment of Hodgkin Lymphoma: A 50-Year Perspective. Journal Of Clinical Oncology 2014, 32: 163-168. PMID: 24441526, DOI: 10.1200/jco.2013.53.1194.
Emil Frei III: A Personal RemembranceCanellos G, DeVita V. Emil Frei III: A Personal Remembrance. The Oncologist 2013, 18: 892-893. PMCID: PMC3720644, DOI: 10.1634/theoncologist.2013-0214.
Letter From the EditorsDeVita V, Lawrence T, Rosenberg S. Letter From the Editors. The Cancer Journal 2007, 13: 1. DOI: 10.1097/ppo.0b013e318053e2f6.
A Prospective Trial of Radiation Alone vs Combination Chemotherapy Alone for Early-Stage Hodgkin's Disease: Implications of 25-Year Follow-Up to Current Combined Modality Therapy.Longo D, Glatstein E, Duffey P, Young R, Fiem S, Jaffe E, Camphausen K, Wilson W, DeVita V. A Prospective Trial of Radiation Alone vs Combination Chemotherapy Alone for Early-Stage Hodgkin's Disease: Implications of 25-Year Follow-Up to Current Combined Modality Therapy. Blood 2006, 108: 98. DOI: 10.1182/blood.v108.11.98.98.
FROM THE EDITORSDeVita V, Hellman S, Rosenberg S. FROM THE EDITORS. The Cancer Journal 2003, 9: 231. DOI: 10.1097/00130404-200307000-00001.
FROM THE EDITORSDeVita V, Hellman S, Rosenberg S. FROM THE EDITORS. The Cancer Journal 2003, 9: 147. DOI: 10.1097/00130404-200305000-00001.
FROM THE EDITORSDeVita V, Hellman S, Rosenberg S. FROM THE EDITORS. The Cancer Journal 2003, 9: 1. DOI: 10.1097/00130404-200301000-00001.
FROM THE EDITORSDeVita V, Hellman S, Rosenberg S. FROM THE EDITORS. The Cancer Journal 2002, 8: 415. DOI: 10.1097/00130404-200211000-00001.
FROM THE EDITORSDeVita V, Hellman S, Rosenberg S. FROM THE EDITORS. The Cancer Journal 2002, 8: 351. DOI: 10.1097/00130404-200209000-00001.
FROM THE EDITORSDeVita V, Hellman S, Rosenberg S. FROM THE EDITORS. The Cancer Journal 2002, 8: 287. DOI: 10.1097/00130404-200207000-00001.
FROM THE EDITORSDeVita V, Hellman S, Rosenberg S. FROM THE EDITORS. The Cancer Journal 2002, 8: 207. DOI: 10.1097/00130404-200205000-00001.
Paul Carbone: 1931-2002DeVita V. Paul Carbone: 1931-2002. The Oncologist 2002, 7: 92-93. DOI: 10.1634/theoncologist.7-2-92.
FROM THE EDITORSDeVita V, Hellman S, Rosenberg S. FROM THE EDITORS. The Cancer Journal 2002, 8: 81. DOI: 10.1097/00130404-200203000-00001.
Therapeutic implications of the new biology.DeVita V, Abou-Alfa G. Therapeutic implications of the new biology. The Cancer Journal 2000, 6 Suppl 2: s113-20. PMID: 10803824.
The lymphomas.DeVita V, Canellos G. The lymphomas. Seminars In Hematology 1999, 36: 84-94. PMID: 10595757.
Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.Longo D, Glatstein E, Duffey P, Young R, Ihde D, Bastian A, Wilson W, Wittes R, Jaffe E, Hubbard S, DeVita V. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. Journal Of Clinical Oncology 1997, 15: 3338-46. PMID: 9363863, DOI: 10.1200/jco.1997.15.11.3338.
Late sequelae of treatment of Hodgkin's diseaseDeVita V. Late sequelae of treatment of Hodgkin's disease. Current Opinion In Oncology 1997, 9: 428-431. PMID: 9327220, DOI: 10.1097/00001622-199709050-00006.
OncologyDeVita V, Deisseroth A. Oncology. JAMA 1996, 275: 1833-1834. PMID: 8642736, DOI: 10.1001/jama.1996.03530470061036.
Diffuse Small Noncleaved-Cell, Non-Burkitt's Lymphoma in AdultsLongo D, Duffey P, Jaffe E, Raffeld M, Hubbard S, Fisher R, Wittes R, DeVita V, Young R. Diffuse Small Noncleaved-Cell, Non-Burkitt's Lymphoma in Adults. Journal Of Clinical Oncology 1996, 14: 1969-1969. DOI: 10.1200/jco.1996.14.6.1969.
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.Longo D, Duffey P, Jaffe E, Raffeld M, Hubbard S, Fisher R, Wittes R, DeVita V, Young R. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. Journal Of Clinical Oncology 1994, 12: 2153-9. PMID: 7523607, DOI: 10.1200/jco.1994.12.10.2153.
Lymphomas.Kwak L, DeVita V, Longo D. Lymphomas. 1994, 15: 413-70. PMID: 7779591.
Dose IntensitySURBONE A, DeVITA V. Dose Intensity. Annals Of The New York Academy Of Sciences 1993, 698: 279-288. PMID: 8279768, DOI: 10.1111/j.1749-6632.1993.tb17219.x.
CHOP versus Intensive Regimens in Non-Hodgkin's LymphomaLongo D, DeVita V, Young R. CHOP versus Intensive Regimens in Non-Hodgkin's Lymphoma. New England Journal Of Medicine 1993, 329: 580-582. PMID: 7687747, DOI: 10.1056/nejm199308193290817.
Hodgkin's DiseaseWood A, DeVita V, Hubbard S. Hodgkin's Disease. New England Journal Of Medicine 1993, 328: 560-565. PMID: 8426624, DOI: 10.1056/nejm199302253280808.
Lymphomas.Kwak L, DeVita V, Longo D. Lymphomas. 1993, 14: 383-426. PMID: 8312110.
Radiation therapy is better than chemotherapy in early-stage Hodgkin's disease? Not so fast.Longo D, Duffey P, Hubbard S, Young R, DeVita V. Radiation therapy is better than chemotherapy in early-stage Hodgkin's disease? Not so fast. Journal Of Clinical Oncology 1992, 10: 1367-9. PMID: 1634930, DOI: 10.1200/jco.1992.10.8.1367.
Biologic Therapy of CancerReid R, DeVita V, Hellman S, Rosenberg S. Biologic Therapy of Cancer. Histopathology 1992, 20: 278-278. DOI: 10.1111/j.1365-2559.1992.tb00973.x.
Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure.Longo D, Duffey P, Young R, Hubbard S, Ihde D, Glatstein E, Phares J, Jaffe E, Urba W, DeVita V. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. Journal Of Clinical Oncology 1992, 10: 210-8. PMID: 1732422, DOI: 10.1200/jco.1992.10.2.210.
The use of combination chemotherapy in the treatment of early stage Hodgkin's disease.Longo D, DeVita V. The use of combination chemotherapy in the treatment of early stage Hodgkin's disease. Important Advances In Oncology 1992, 155-65. PMID: 1582671.
Lymphomas.Longo D, DeVita V. Lymphomas. 1992, 13: 349-403. PMID: 1389915.
The calculation of actual or received dose intensity: a comparison of published methods.Longo D, Duffey P, DeVita V, Wesley M, Hubbard S, Young R. The calculation of actual or received dose intensity: a comparison of published methods. Journal Of Clinical Oncology 1991, 9: 2042-51. PMID: 1941063, DOI: 10.1200/jco.1991.9.11.2042.
Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.Longo D, Duffey P, DeVita V, Wiernik P, Hubbard S, Phares J, Bastian A, Jaffe E, Young R. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. Journal Of Clinical Oncology 1991, 9: 1409-20. PMID: 1712836, DOI: 10.1200/jco.1991.9.8.1409.
Important Advances in OncologyDeVita V, Hellman S, Rosenberg S. Important Advances in Oncology. Anti-Cancer Drugs 1991, 2: 419. DOI: 10.1097/00001813-199108000-00014.
Superiority of ProMACE-CytaBOM Over ProMACE-MOPP in the Treatment of Advanced Diffuse Aggressive LymphomaLongo D, DeVita V, Duffey P, Wesley M, Ihde D, Hubbard S, Gilliom M, Jaffe E, Cossman J, Fisher R, Young R. Superiority of ProMACE-CytaBOM Over ProMACE-MOPP in the Treatment of Advanced Diffuse Aggressive Lymphoma. Journal Of Clinical Oncology 1991, 9: 710-710. DOI: 10.1200/jco.1991.9.4.710.
The influence of information on drug resistance on protocol design The Henry Kaplan Memorial Lecture, International Conference on Mulignant Lymphomas, 6–9 June 1990, Lugano, SwitzerlandDeVita V. The influence of information on drug resistance on protocol design The Henry Kaplan Memorial Lecture, International Conference on Mulignant Lymphomas, 6–9 June 1990, Lugano, Switzerland. Annals Of Oncology 1991, 2: 93-106. PMID: 2054322, DOI: 10.1093/oxfordjournals.annonc.a057892.
Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.Longo D, Russo A, Duffey P, Hubbard S, Glatstein E, Hill J, Jaffe E, Young R, DeVita V. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. Journal Of Clinical Oncology 1991, 9: 227-35. PMID: 1988570, DOI: 10.1200/jco.1991.9.2.227.
Lymphomas.Longo D, Devita V. Lymphomas. 1991, 12: 347-93. PMID: 1931450.
Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.Longo D, DeVita V, Duffey P, Wesley M, Ihde D, Hubbard S, Gilliom M, Jaffe E, Cossman J, Fisher R. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. Journal Of Clinical Oncology 1991, 9: 25-38. PMID: 1702144, DOI: 10.1200/jco.1991.9.1.25.
Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomasFisher R, Longo D, DeVita V, Hubbard S, Miller T, Young R. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas. Annals Of Oncology 1991, 2: 33-35. PMID: 1710487, DOI: 10.1093/annonc/2.suppl_1.33.
Lymphomas.Longo D, DeVita V. Lymphomas. 1990, 11: 343-78. PMID: 2223399.
Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy.Longo D, Glatstein E, Duffey P, Ihde D, Hubbard S, Fisher R, Jaffe E, Gilliom M, Young R, DeVita V. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. Journal Of Clinical Oncology 1989, 7: 1295-302. PMID: 2788716, DOI: 10.1200/jco.1989.7.9.1295.
Breast Cancer Therapy: Exercising All Our OptionsDeVita V. Breast Cancer Therapy: Exercising All Our Options. New England Journal Of Medicine 1989, 320: 527-529. PMID: 2915656, DOI: 10.1056/nejm198902233200812.
Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.Surbone A, Longo D, DeVita V, Ihde D, Duffey P, Jaffe E, Solomon D, Hubbard S, Young R. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. Journal Of Clinical Oncology 1988, 6: 1832-7. PMID: 3199167, DOI: 10.1200/jco.1988.6.12.1832.
Keeping up with the cancer literature--PDQ ACCESS.Perry D, Sloane E, Hubbard S, Tingley D, DeVita V. Keeping up with the cancer literature--PDQ ACCESS. Journal Of Clinical Oncology 1988, 6: 1649-52. PMID: 3171630, DOI: 10.1200/jco.1988.6.10.1649.
The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.Young R, Longo D, Glatstein E, Ihde D, Jaffe E, DeVita V. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Seminars In Hematology 1988, 25: 11-6. PMID: 2456618.
The role of chemotherapy in diffuse aggressive lymphomas.DeVita V, Hubbard S, Young R, Longo D. The role of chemotherapy in diffuse aggressive lymphomas. Seminars In Hematology 1988, 25: 2-10. PMID: 3041598.
Lymphomas.Longo D, Devita V. Lymphomas. 1988, 10: 148-81. PMID: 3079382.
A computer data base for information on cancer treatmentHubbard S, Henney J, DeVita V. A computer data base for information on cancer treatment. CA A Cancer Journal For Clinicians 1987, 37: 186-192. DOI: 10.3322/canjclin.37.3.186.
Developmental therapeutics and the acquired immunodeficiency syndrome.DeVita V, Broder S, Fauci A, Kovacs J, Chabner B. Developmental therapeutics and the acquired immunodeficiency syndrome. Annals Of Internal Medicine 1987, 106: 568-81. PMID: 2435201, DOI: 10.7326/0003-4819-106-4-568.
Decreasing Risk of Leukemia with Prolonged Follow-up after Chemotherapy and Radiotherapy for Hodgkin's DiseaseBlayney D, Longo D, Young R, Greene M, Hubbard S, Postal M, Duffey P, DeVita V. Decreasing Risk of Leukemia with Prolonged Follow-up after Chemotherapy and Radiotherapy for Hodgkin's Disease. New England Journal Of Medicine 1987, 316: 710-714. PMID: 3821809, DOI: 10.1056/nejm198703193161203.
The Emergence of Biologicals as Cancer Treatment: The Good News and The BadDevita V, Roper M. The Emergence of Biologicals as Cancer Treatment: The Good News and The Bad. Hospital Practice 1987, 22: 15-21. PMID: 3100560, DOI: 10.1080/21548331.1987.11707666.
A Computer Data Base for Information on Cancer TreatmentHubbard S, Henney J, DeVita V. A Computer Data Base for Information on Cancer Treatment. New England Journal Of Medicine 1987, 316: 315-318. PMID: 3543675, DOI: 10.1056/nejm198702053160606.
MOPP after two decades.Longo D, Young R, Duffey P, Hubbard S, DeVita V. MOPP after two decades. Journal Of Clinical Oncology 1987, 5: 320-1. PMID: 3806177, DOI: 10.1200/jco.1987.5.2.320.
The lymphomas: biologic implications of therapy and therapeutic implications of the new biology.DeVita V, Longo D, Hubbard S, Young R, Chabner B. The lymphomas: biologic implications of therapy and therapeutic implications of the new biology. International Academy Of Pathology Monograph 1987, 249-67. PMID: 3295522.
Lymphomas.Longo D, Devita V. Lymphomas. 1987, 9: 165-99. PMID: 3079402.
Twenty years of MOPP therapy for Hodgkin's disease.Longo D, Young R, Wesley M, Hubbard S, Duffey P, Jaffe E, DeVita V. Twenty years of MOPP therapy for Hodgkin's disease. Journal Of Clinical Oncology 1986, 4: 1295-306. PMID: 3528400, DOI: 10.1200/jco.1986.4.9.1295.
The Next Fifteen YearsDeVita V. The Next Fifteen Years. Oncology Issues 1986, 1: 15-15. DOI: 10.1080/08986053.1986.11904865.
The effect of combined modality therapy on local control and survivalDeVita V, Lippman M, Hubbard S, Ihde D, Rosenberg S. The effect of combined modality therapy on local control and survival. International Journal Of Radiation Oncology • Biology • Physics 1986, 12: 487-501. PMID: 3009367, DOI: 10.1016/0360-3016(86)90056-8.
The Physician Data Query (PDQ) cancer information system.Hubbard S, Martin N, Blankenbaker L, Esterhay R, Masys D, Tingley D, Stram M, DeVita V. The Physician Data Query (PDQ) cancer information system. Journal Of Cancer Education 1986, 1: 79-87. PMID: 3079208, DOI: 10.1080/08858198609527818.
Current Management of Hodgkin’s DiseaseBehrens B, Young R, DeVita V. Current Management of Hodgkin’s Disease. Drugs 1985, 30: 355-367. PMID: 3905335, DOI: 10.2165/00003495-198530040-00004.
Abnormal coagulation results in patients with hodgkin's diseaseSeifter E, Parker R, Gralnick H, Wesley M, DeVita V, Young R, Longo D. Abnormal coagulation results in patients with hodgkin's disease. The American Journal Of Medicine 1985, 78: 942-950. PMID: 3160235, DOI: 10.1016/0002-9343(85)90216-5.
Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy.Geffen D, Fisher R, Longo D, Young R, DeVita V. Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy. Journal Of Clinical Oncology 1985, 3: 646-53. PMID: 3998781, DOI: 10.1200/jco.1985.3.5.646.
ProMACE-MOPP combination chemotherapy for diffuse lymphomas.Fisher R, Young R, Longo D, DeVita V. ProMACE-MOPP combination chemotherapy for diffuse lymphomas. Seminars In Oncology 1985, 12: 29-32. PMID: 2579441.
The current status of NCI trials in Hodgkin’s diseaseYoung R, Longo D, Glatstein E, Duffey P, Winkler C, Wiernik P, Devita V. The current status of NCI trials in Hodgkin’s disease. 1985, 293-298. DOI: 10.1007/978-1-4613-2607-6_30.
Treatment of diffuse large cell non-Hodgkin’s lymphomasFisher R, Devita V, Longo D, Ihde D, Young R. Treatment of diffuse large cell non-Hodgkin’s lymphomas. 1985, 465-469. DOI: 10.1007/978-1-4613-2607-6_49.
Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience.Tester W, Kinsella T, Waller B, Makuch R, Kelley P, Glatstein E, DeVita V. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. Journal Of Clinical Oncology 1984, 2: 762-9. PMID: 6547479, DOI: 10.1200/jco.1984.2.7.762.
Prolonged initial remission in patients with nodular mixed lymphoma.Longo D, Young R, Hubbard S, Wesley M, Fisher R, Jaffe E, Berard C, DeVita V. Prolonged initial remission in patients with nodular mixed lymphoma. Annals Of Internal Medicine 1984, 100: 651-6. PMID: 6370065, DOI: 10.7326/0003-4819-100-5-651.
NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus.Broder S, Bunn P, Jaffe E, Blattner W, Gallo R, Wong-Staal F, Waldmann T, DeVita V. NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Annals Of Internal Medicine 1984, 100: 543-57. PMID: 6322632, DOI: 10.7326/0003-4819-100-4-543.
25 THERAPEUTIC RESEARCH IN THE NATIONAL CANCER INSTITUTEDeVita V, Goidin A. 25 THERAPEUTIC RESEARCH IN THE NATIONAL CANCER INSTITUTE. 1984, 499-526. DOI: 10.1016/b978-0-12-667980-9.50032-4.
Progress in cancer management. Keynote addressDevita V. Progress in cancer management. Keynote address. Cancer 1983, 51: 2401-2409. PMID: 6342749, DOI: 10.1002/1097-0142(19830615)51:12+<2401::aid-cncr2820511302>3.0.co;2-7.
The james ewing lecture. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancerDevita V. The james ewing lecture. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer. Cancer 1983, 51: 1209-1220. PMID: 6825044, DOI: 10.1002/1097-0142(19830401)51:7<1209::aid-cncr2820510707>3.0.co;2-j.
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.Fisher R, DeVita V, Hubbard S, Longo D, Wesley R, Chabner B, Young R. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Annals Of Internal Medicine 1983, 98: 304-9. PMID: 6600902, DOI: 10.7326/0003-4819-98-3-304.
The cure of Hodgkin's disease with drugs.DeVita V, Hubbard S, Moxley J. The cure of Hodgkin's disease with drugs. Advances In Internal Medicine 1983, 28: 277-302. PMID: 6188346.
Malignant lymphoma II. Prognostic factors and response to treatment of 473 patients at the national cancer instituteAnderson T, Devita V, Simon R, Berard C, Canellos G, Garvin A, Young R. Malignant lymphoma II. Prognostic factors and response to treatment of 473 patients at the national cancer institute. Cancer 1982, 50: 2708-2721. PMID: 7139564, DOI: 10.1002/1097-0142(19821215)50:12<2708::aid-cncr2820501203>3.0.co;2-g.
Malignant lymphoma I. The histology and staging of 473 patients at the national cancer instituteAnderson T, Chabner B, Young R, Berard C, Garvin AJ, Simon R, Devita V. Malignant lymphoma I. The histology and staging of 473 patients at the national cancer institute. Cancer 1982, 50: 2699-2707. PMID: 7139563, DOI: 10.1002/1097-0142(19821215)50:12<2699::aid-cncr2820501202>3.0.co;2-a.
Undifferentiated non‐Hodgkin'S lymphomas (Burkitt's and non‐Burkitt's types). The relevance of making this histologic distinctionMiliauskas J, Berard C, Young R, Garvin A, Edwards B, Devita V. Undifferentiated non‐Hodgkin'S lymphomas (Burkitt's and non‐Burkitt's types). The relevance of making this histologic distinction. Cancer 1982, 50: 2115-2121. PMID: 7127252, DOI: 10.1002/1097-0142(19821115)50:10<2115::aid-cncr2820501024>3.0.co;2-9.
Changing patterns of Hodgkin's disease at autopsy: a 25-year experience at the National Cancer Institute, 1953--1978.Grogan T, Berard C, Steinhorn S, Hankey B, Kant J, Miliauskas J, Young R, DeVita V. Changing patterns of Hodgkin's disease at autopsy: a 25-year experience at the National Cancer Institute, 1953--1978. Journal Of The National Cancer Institute 1982, 66: 653-65. PMID: 7074636.
Chemotherapy for Hodgkin's disease: the remaining challenges.Longo D, Young R, DeVita V. Chemotherapy for Hodgkin's disease: the remaining challenges. Journal Of The National Cancer Institute 1982, 66: 925-36. PMID: 7042091.
Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's diseaseSchilsky R, Sherins R, Hubbard S, Wesley M, Young R, DeVita V. Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. The American Journal Of Medicine 1981, 71: 552-556. PMID: 7282743, DOI: 10.1016/0002-9343(81)90205-9.
Factors Predicting Long-Term Survival in Diffuse Mixed, Histiocytic, or Undifferentiated LymphomaFisher R, Hubbard S, DeVita V, Berard C, Wesley R, Cossman J, Young R. Factors Predicting Long-Term Survival in Diffuse Mixed, Histiocytic, or Undifferentiated Lymphoma. Blood 1981, 58: 45-51. DOI: 10.1182/blood.v58.1.45.45.
Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma.Fisher R, Hubbard S, DeVita V, Berard C, Wesley R, Cossman J, Young R. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 1981, 58: 45-51. PMID: 7236892, DOI: 10.1182/blood.v58.1.45.bloodjournal58145.
Natural history of malignant lymphomas with divergent histologies at staging evaluationFisher R, Jones R, Devita V, Simon R, Garvin A, Berard C, Young R. Natural history of malignant lymphomas with divergent histologies at staging evaluation. Cancer 1981, 47: 2022-2025. PMID: 7226096, DOI: 10.1002/1097-0142(19810415)47:8<2022::aid-cncr2820470820>3.0.co;2-v.
Multimodal treatment of primary breast carcinoma Analysis of accomplishments and problem areasWeiss R, Henney J, DeVita V. Multimodal treatment of primary breast carcinoma Analysis of accomplishments and problem areas. The American Journal Of Medicine 1981, 70: 844-851. PMID: 7011024, DOI: 10.1016/0002-9343(81)90541-6.
Current results of the screening program at the division of cancer treatment, national cancer instituteGoldin A, Venditti J, Macdonald J, Muggia F, Henney J, Devita V. Current results of the screening program at the division of cancer treatment, national cancer institute. European Journal Of Cancer 1981, 17: 129-142. PMID: 6894902, DOI: 10.1016/0014-2964(81)90027-x.
The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lectureDevita V. The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lecture. Cancer 1981, 47: 1-13. PMID: 6970069, DOI: 10.1002/1097-0142(19810101)47:1<1::aid-cncr2820470102>3.0.co;2-2.
Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphomaBroder S, Callihan T, Jaffe E, DeVita V, Strober W, Bartter F, Waldmann T. Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma. Gastroenterology 1981, 80: 166-168. PMID: 7450403, DOI: 10.1016/0016-5085(81)90208-0.
Animal toxicology for early clinical trials with anticancer agents.Rozencweig M, Von Hoff D, Staquet M, Schein P, Penta J, Goldin A, Muggia F, Freireich E, DeVita V. Animal toxicology for early clinical trials with anticancer agents. American Journal Of Clinical Oncology 1981, 4: 21-8. PMID: 6783332.
Non-Hodgkin's lymphomas in leukemic phase: Clinicopathologic correlationsCome S, Jaffe E, Andersen J, Mann R, Johnson B, DeVita V, Young R. Non-Hodgkin's lymphomas in leukemic phase: Clinicopathologic correlations. The American Journal Of Medicine 1980, 69: 667-674. PMID: 7001897, DOI: 10.1016/0002-9343(80)90416-7.
The evolution of primary multimodality treatment in resectable breast cancerHenney J, Devita V. The evolution of primary multimodality treatment in resectable breast cancer. Cancer 1980, 46: 999-1008. PMID: 6994877, DOI: 10.1002/1097-0142(19800815)46:4+<999::aid-cncr2820461325>3.0.co;2-e.
Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease.Fisher R, DeVita V, Bostick F, Vanhaelen C, Howser D, Hubbard S, Young R. Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. Annals Of Internal Medicine 1980, 92: 595-9. PMID: 6992672, DOI: 10.7326/0003-4819-92-5-595.
General Progress in Clinical Chemotherapy of Advanced DiseaseMuggia F, Henney J, DeVita V. General Progress in Clinical Chemotherapy of Advanced Disease. 1980, 74: 1-7. PMID: 7003657, DOI: 10.1007/978-3-642-81488-4_1.
Chemotherapy of Hodgkin's diseaseYoung R, DeVita V. Chemotherapy of Hodgkin's disease. Clinics In Haematology 1979, 8: 625-644. PMID: 91466, DOI: 10.1016/s0308-2261(79)80007-7.
Human models of human diseases; breast cancer and the lymphomasDevita V. Human models of human diseases; breast cancer and the lymphomas. International Journal Of Radiation Oncology • Biology • Physics 1979, 5: 1855-1867. PMID: 393666, DOI: 10.1016/0360-3016(79)90571-6.
The role of combined modality therapy in the treatment of stage IIIA Hodgkin's diseaseDevita V. The role of combined modality therapy in the treatment of stage IIIA Hodgkin's disease. International Journal Of Radiation Oncology • Biology • Physics 1979, 5: 913. PMID: 500419, DOI: 10.1016/0360-3016(79)90077-4.
A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non‐Hodgkin's lymphomaBrereton H, Young R, Longo D, Kirkland L, Berard C, Jaffe E, Devita V, Johnson R. A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non‐Hodgkin's lymphoma. Cancer 1979, 43: 2227-2231. PMID: 378350, DOI: 10.1002/1097-0142(197906)43:6<2227::aid-cncr2820430611>3.0.co;2-j.
Advanced Ovarian Adenocarcinoma A Prospective Clinical Trial of Melphalan (L-PAM) Versus Combination ChemotherapyYoung R, Chabner B, Hubbard S, Fisher R, Bender R, Anderson T, Simon R, Canellos G, Devita V. Advanced Ovarian Adenocarcinoma A Prospective Clinical Trial of Melphalan (L-PAM) Versus Combination Chemotherapy. Obstetrical & Gynecological Survey 1979, 34: 414. DOI: 10.1097/00006254-197905000-00027.
Central nervous system complications of non-Hodgkin's lymphoma The potential role for prophylactic therapyYoung R, Howser D, Anderson T, Fisher R, Jaffe E, DeVita V. Central nervous system complications of non-Hodgkin's lymphoma The potential role for prophylactic therapy. The American Journal Of Medicine 1979, 66: 435-443. PMID: 433950, DOI: 10.1016/0002-9343(79)91065-9.
CNS Infiltration: A Complication of Diffuse LymphomasYoung R, Howser D, Anderson T, Jaffe E, DeVita V. CNS Infiltration: A Complication of Diffuse Lymphomas. 1979, 121-130. DOI: 10.1007/978-1-349-04285-2_11.
Combination chemotherapy of acute leukemia and lymphomaLewis B, DeVita V. Combination chemotherapy of acute leukemia and lymphoma. Pharmacology & Therapeutics 1979, 7: 91-121. PMID: 392552, DOI: 10.1016/0163-7258(79)90026-3.
Clinical Relevance of the Histopathological Subclassification of Diffuse Histiocytic LymphomaStrauchen J, Young R, Devita V, Anderson T, Fantone J, Berard C. Clinical Relevance of the Histopathological Subclassification of Diffuse Histiocytic Lymphoma. New England Journal Of Medicine 1978, 299: 1382-1387. PMID: 362206, DOI: 10.1056/nejm197812212992503.
Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination ChemotherapyYoung R, Chabner B, Hubbard S, Fisher R, Bender R, Anderson T, Simon R, Canellos G, DeVita V. Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy. New England Journal Of Medicine 1978, 299: 1261-1266. PMID: 101843, DOI: 10.1056/nejm197812072992301.
Hexamethylmelamine in alkylating agent‐resistant ovarian carcinomaJohnson B, Fisher R, Bender R, Devita V, Chabner B, Young R. Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma. Cancer 1978, 42: 2157-2161. PMID: 102417, DOI: 10.1002/1097-0142(197811)42:5<2157::aid-cncr2820420511>3.0.co;2-7.
High volume intraperitoneal chemotherapy (“Belly bath”) for ovarian cancerJones R, Myers C, Guarino A, Dedrick R, Hubbard S, DeVita V. High volume intraperitoneal chemotherapy (“Belly bath”) for ovarian cancer. Cancer Chemotherapy And Pharmacology 1978, 1: 161-166. PMID: 373916, DOI: 10.1007/bf00253116.
Sequential nonsurgical and surgical staging of non‐Hodgkin's lymphomaChabner B, Johnson R, Young R, Canellos G, Hubbard S, Johnson S, Devita V. Sequential nonsurgical and surgical staging of non‐Hodgkin's lymphoma. Cancer 1978, 42: 922-925. PMID: 150938, DOI: 10.1002/1097-0142(197808)42:2+<922::aid-cncr2820420714>3.0.co;2-9.
The chemotherapy of Hodgkin's disease. Past experiences and future directionsDevita V, Lewis B, Rozencweig M, Muggia F. The chemotherapy of Hodgkin's disease. Past experiences and future directions. Cancer 1978, 42: 979-990. PMID: 356960, DOI: 10.1002/1097-0142(197808)42:2+<979::aid-cncr2820420721>3.0.co;2-s.
Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapyYoung R, Canellos G, Chabner B, Hubbard S, Devita V. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer 1978, 42: 1001-1007. PMID: 688174, DOI: 10.1002/1097-0142(197808)42:2+<1001::aid-cncr2820420723>3.0.co;2-z.
Diffuse histiocytic lymphoma involving the gastrointestinal tractHande K, Fisher R, Devita V, Chabner B, Young R. Diffuse histiocytic lymphoma involving the gastrointestinal tract. Cancer 1978, 41: 1984-1989. PMID: 348299, DOI: 10.1002/1097-0142(197805)41:5<1984::aid-cncr2820410544>3.0.co;2-8.
The Evolution of Therapeutic Research in CancerDeVita V. The Evolution of Therapeutic Research in Cancer. New England Journal Of Medicine 1978, 298: 907-910. PMID: 634335, DOI: 10.1056/nejm197804202981610.
Randomized comparison of chemotherapy (CVP) and radiotherapy (TBI) in stage III–IV poorly differentiated lymphocytic lymphomaJohnson R, Canellos G, Young R, Chabner B, DeVita V. Randomized comparison of chemotherapy (CVP) and radiotherapy (TBI) in stage III–IV poorly differentiated lymphocytic lymphoma. International Journal Of Radiation Oncology • Biology • Physics 1978, 4: 33. DOI: 10.1016/0360-3016(78)90617-x.
New Anticancer DrugsMuggia F, Bono V, DeVita V. New Anticancer Drugs. 1978, 23: 42-49. PMID: 646328, DOI: 10.1159/000401470.
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.Dedrick R, Myers C, Bungay P, DeVita V. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Journal Of The National Cancer Institute 1978, 62: 1-11. PMID: 626987.
Letter to the editorMuggia F, Devita V. Letter to the editor. Pediatric Blood & Cancer 1978, 4: 181-181. PMID: 661754, DOI: 10.1002/mpo.2950040215.
Invited commentaryDeVita V. Invited commentary. World Journal Of Surgery 1978, 2: 105-107. DOI: 10.1007/bf01574474.
Risk of new cancers in patients with Hodgkin's diseaseArseneau J, Canellos G, Johnson R, Devita V. Risk of new cancers in patients with Hodgkin's disease. Cancer 1977, 40: 1912-1916. PMID: 907993, DOI: 10.1002/1097-0142(197710)40:4+<1912::aid-cncr2820400823>3.0.co;2-d.
Peritoneoscopy: a technique to evaluate therapeutic efficacy in non-Hodgkin's lymphoma patients.Anderson T, Bender R, Rosenoff S, Brereton H, Chabner B, DeVita V, Hubbard S, Young R. Peritoneoscopy: a technique to evaluate therapeutic efficacy in non-Hodgkin's lymphoma patients. Journal Of The National Cancer Institute 1977, 61: 1017-22. PMID: 143345.
Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup.Anderson T, Bender R, Fisher R, DeVita V, Chabner B, Berard C, Norton L, Young R. Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. Journal Of The National Cancer Institute 1977, 61: 1057-66. PMID: 71205.
Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination.Young R, Johnson R, Canellos G, Chabner B, Brereton H, Berard C, DeVita V. Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Journal Of The National Cancer Institute 1977, 61: 1153-9. PMID: 332349.
Hodgkin's disease: The salvage of radiation treatment failuresDeVita V. Hodgkin's disease: The salvage of radiation treatment failures. International Journal Of Radiation Oncology • Biology • Physics 1977, 2: 1035-1037. PMID: 591399, DOI: 10.1016/0360-3016(77)90208-5.
Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapyFisher R, DeVita V, Johnson B, Simon R, Young R. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. The American Journal Of Medicine 1977, 63: 177-182. PMID: 70170, DOI: 10.1016/0002-9343(77)90230-3.
The treatment of Hodgkin's diseaseYoung R, Anderson T, DeVita V. The treatment of Hodgkin's disease. Current Problems In Cancer 1977, 1: 1-29. PMID: 66119, DOI: 10.1016/s0147-0272(77)80009-3.
Combined modality treatment of American Burkittapos;s lymphomaZiegler J, Devita V, Graw R, Herzig G, Leventhal B, Levine A, Pomeroy T. Combined modality treatment of American Burkittapos;s lymphoma. Cancer 1976, 38: 2225-2231. PMID: 1036716, DOI: 10.1002/1097-0142(197612)38:6<2225::aid-cncr2820380606>3.0.co;2-f.
Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.Schein P, DeVita V, Hubbard S, Chabner B, Canellos G, Berard C, Young R. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Annals Of Internal Medicine 1976, 85: 417-22. PMID: 61732, DOI: 10.7326/0003-4819-85-4-417.
A Phase I–II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid TumorsRobinson R, DeVita V, Levy H, Baron S, Hubbard S, Levine A. A Phase I–II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid Tumors. Journal Of The National Cancer Institute 1976, 57: 599-602. PMID: 978771, DOI: 10.1093/jnci/57.3.599.
Treatment of hodgkin's disease using intensive chemotherapy followed by irradiationKun L, Devita V, Young R, Johnson R. Treatment of hodgkin's disease using intensive chemotherapy followed by irradiation. International Journal Of Radiation Oncology • Biology • Physics 1976, 1: 619-626. PMID: 824248, DOI: 10.1016/0360-3016(76)90143-7.
Perspectives on research in gynecologic oncology. Treatment protocolsDevita V, Wasserman T, Young R, Carter S. Perspectives on research in gynecologic oncology. Treatment protocols. Cancer 1976, 38: 509-525. PMID: 776390, DOI: 10.1002/1097-0142(197607)38:1<509::aid-cncr2820380175>3.0.co;2-a.
Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy.Canellos G, DeVita V, Whang-Peng J, Chabner B, Schein P, Young R. Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy. Blood 1976, 47: 1003-9. PMID: 1064434, DOI: 10.1182/blood.v47.6.1003.bloodjournal4761003.
Chemotherapy of the Blastic Phase of Chronic Granulocytic Leukemia: Hypodiploidy and Response to TherapyCanellos G, DeVita V, Whang-Peng J, Chabner B, Schein P, Young R. Chemotherapy of the Blastic Phase of Chronic Granulocytic Leukemia: Hypodiploidy and Response to Therapy. Blood 1976, 47: 1003-1009. DOI: 10.1182/blood.v47.6.1003.1003.
Combination chemotherapy for advanced breast cancer: response and effect on survival.Canellos G, DeVita V, Gold G, Chabner B, Schein P, Young R. Combination chemotherapy for advanced breast cancer: response and effect on survival. Annals Of Internal Medicine 1976, 84: 389-92. PMID: 1259283, DOI: 10.7326/0003-4819-84-4-389.
Pneumocystis PneumoniaMICHAELIS L, LEIGHT G, POWELL R, DEVITA V. Pneumocystis Pneumonia. Annals Of Surgery 1976, 183: 301-306. PMID: 1083218, PMCID: PMC1344242, DOI: 10.1097/00000658-197603000-00016.
Pathological staging of 100 consecutive untreated patients with non‐Hodgkin's lymphomas. Extramedullary sites of diseaseLotz M, Chabner B, Devita V, Johnson R, Berard C. Pathological staging of 100 consecutive untreated patients with non‐Hodgkin's lymphomas. Extramedullary sites of disease. Cancer 1976, 37: 266-270. PMID: 1247961, DOI: 10.1002/1097-0142(197601)37:1<266::aid-cncr2820370136>3.0.co;2-z.
Meningeal leukemia in the blastic phase of chronic granulocytic leukemiaSchwartz J, Canellos G, Young R, DeVita V. Meningeal leukemia in the blastic phase of chronic granulocytic leukemia. The American Journal Of Medicine 1975, 59: 819-828. PMID: 1059328, DOI: 10.1016/0002-9343(75)90467-2.
Osteonecrosis of the femoral head in patients with lymphoma treated with intermittent combination chemotherapy (including corticosteroids)Ihde D, Devita V. Osteonecrosis of the femoral head in patients with lymphoma treated with intermittent combination chemotherapy (including corticosteroids). Cancer 1975, 36: 1585-1588. PMID: 1192349, DOI: 10.1002/1097-0142(197511)36:5<1585::aid-cncr2820360508>3.0.co;2-d.
High dose intravenous bleomycin in the treatment of advanced lymphomasHubbard S, Chabner B, Canellos G, Young R, DeVita V. High dose intravenous bleomycin in the treatment of advanced lymphomas. European Journal Of Cancer 1975, 11: 623-626. PMID: 56271, DOI: 10.1016/0014-2964(75)90096-1.
Peritoneoscopy: a valuable staging tool in ovarian carcinoma.Rosenoff S, Young R, Anderson T, Bagley C, Chabner B, Schein P, Hubbard S, DeVita V. Peritoneoscopy: a valuable staging tool in ovarian carcinoma. Annals Of Internal Medicine 1975, 83: 37-41. PMID: 125057, DOI: 10.7326/0003-4819-83-1-37.
The American Burkitt Lymphoma Registry: a progress report.Levine P, Connelly R, Berard C, O'Connor G, Dorfman R, EASTON J, DeVita V. The American Burkitt Lymphoma Registry: a progress report. Annals Of Internal Medicine 1975, 83: 31-6. PMID: 1147436, DOI: 10.7326/0003-4819-83-1-31.
Single agent versus combination chemotherapyDeVita V. Single agent versus combination chemotherapy. CA A Cancer Journal For Clinicians 1975, 25: 152-158. PMID: 165865, DOI: 10.3322/canjclin.25.3.152.
Percutaneous liver biopsy, peritoneoscopy and laparotomy: an assessment of relative merits in the lymphomata.Chabner B, Johnson R, Chretien P, Schein P, Young R, Canellos C, Hubbard S, Anderson T, Rosenoff S, DeVita V. Percutaneous liver biopsy, peritoneoscopy and laparotomy: an assessment of relative merits in the lymphomata. British Journal Of Cancer. Supplement 1975, 2: 242-7. PMID: 126693, PMCID: PMC2149568.
Patterns of involvement with malignant lymphoma and implications for treatment decision making.Johnson R, DeVita V, Kun L, Chabner B, Chretien P, Berard C, Johnson S. Patterns of involvement with malignant lymphoma and implications for treatment decision making. British Journal Of Cancer. Supplement 1975, 2: 237-41. PMID: 1182071, PMCID: PMC2149575.
Therapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy.Canellos G, DeVita V, Young R, Chabner B, Schein P, Johnson R. Therapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy. British Journal Of Cancer. Supplement 1975, 2: 474-80. PMID: 1101933, PMCID: PMC2149565.
Results of combination chemotherapy of non-Hodgkin's lymphoma.Schein P, Chabner B, Canellos G, Young R, Berard C, DeVita V. Results of combination chemotherapy of non-Hodgkin's lymphoma. British Journal Of Cancer. Supplement 1975, 2: 465-73. PMID: 1101932, PMCID: PMC2149606.
American Burkitt's lymphoma: A clinicopathologic study of 30 cases II. Pathologic correlationsBanks P, Arseneau J, Gralnick H, Canellos G, DeVita V, Berard C. American Burkitt's lymphoma: A clinicopathologic study of 30 cases II. Pathologic correlations. The American Journal Of Medicine 1975, 58: 322-329. PMID: 163581, DOI: 10.1016/0002-9343(75)90598-7.
American Burkitt's lymphoma: A clinicopathologic study of 30 cases I. Clinical factors relating to prolonged survivalArseneau J, Canellos G, Banks P, Berard C, Gralnick H, DeVita V. American Burkitt's lymphoma: A clinicopathologic study of 30 cases I. Clinical factors relating to prolonged survival. The American Journal Of Medicine 1975, 58: 314-321. PMID: 1115074, DOI: 10.1016/0002-9343(75)90597-5.
Non‐Hodgkin's lymphoma: Patterns of relapse from complete remission after combination chemotherapySchein P, Chabner B, Canellos G, Young R, Devita V. Non‐Hodgkin's lymphoma: Patterns of relapse from complete remission after combination chemotherapy. Cancer 1975, 35: 354-357. PMID: 1089470, DOI: 10.1002/1097-0142(197502)35:2<354::aid-cncr2820350209>3.0.co;2-2.
Letter: Combination chemotherapy for breast cancer.Canellos G, DeVita V, Gold G, Chabner B, Schein P, Young R. Letter: Combination chemotherapy for breast cancer. The BMJ 1975, 1: 37. PMID: 1120229, PMCID: PMC1671886, DOI: 10.1136/bmj.1.5948.37-c.
Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancerDevita V, Young R, Canellos G. Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer. Cancer 1975, 35: 98-110. PMID: 162854, DOI: 10.1002/1097-0142(197501)35:1<98::aid-cncr2820350115>3.0.co;2-b.
Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamideYoung R, Canellos G, Chabner B, Schein P, Hubbard S, DeVita V. Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide. Gynecologic Oncology 1974, 2: 489-497. PMID: 4376998, DOI: 10.1016/0090-8258(74)90059-6.
The design of clinical trials in the therapy of ovarian carcinomaYoung R, DeVita V. The design of clinical trials in the therapy of ovarian carcinoma. American Journal Of Obstetrics And Gynecology 1974, 120: 1012-1024. PMID: 4432892, DOI: 10.1016/0002-9378(74)90143-4.
Thrombocytosis in Chronic Granulocytic Leukemia: Incidence and Clinical SignificanceMason J, DeVita V, Canellos G. Thrombocytosis in Chronic Granulocytic Leukemia: Incidence and Clinical Significance. Blood 1974, 44: 483-487. PMID: 4528824, DOI: 10.1182/blood.v44.4.483.483.
Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998)Schein P, O'Connell M, Blom J, Hubbard S, Magrath I, Bergevin P, Wiernik P, Ziegler J, Devita V. Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998). Cancer 1974, 34: 993-1000. PMID: 4371075, DOI: 10.1002/1097-0142(197410)34:4<993::aid-cncr2820340404>3.0.co;2-t.
Indomethacin-Responsive Hypercalcemia in a Patient with Renal-Cell AdenocarcinomaBrereton H, Halushka P, Alexander R, Mason D, Keiser H, DeVita V. Indomethacin-Responsive Hypercalcemia in a Patient with Renal-Cell Adenocarcinoma. New England Journal Of Medicine 1974, 291: 83-85. PMID: 4835887, DOI: 10.1056/nejm197407112910207.
The chemotherapy of ovarian carcinomaYoung R, Hubbard S, DeVita V. The chemotherapy of ovarian carcinoma. Cancer Treatment Reviews 1974, 1: 99-110. DOI: 10.1016/s0305-7372(74)80013-7.
Treatment of malignant melanoma with methyl CCNUYoung R, Canellos G, Chabner B, Schein P, Brereton H, DeVita V. Treatment of malignant melanoma with methyl CCNU. Clinical Pharmacology & Therapeutics 1974, 15: 617-622. PMID: 4601745, DOI: 10.1002/cpt1974156617.
HL-A antigens in Hodgkin's disease; histopathologic and clinical correlations.Graff K, Simon R, Yankee R, DeVita V, Rogentine G. HL-A antigens in Hodgkin's disease; histopathologic and clinical correlations. Journal Of The National Cancer Institute 1974, 52: 1087-90. PMID: 4826579, DOI: 10.1093/jnci/52.4.1087.
BCG Vaccine Treatment of Hodgkin DiseaseDeVita V. BCG Vaccine Treatment of Hodgkin Disease. JAMA 1974, 228: 28-28. PMID: 4406143, DOI: 10.1001/jama.1974.03230260022015.
Radiotherapeutic implications of prospective staging in non-Hodgkin's lymphoma.Johnson R, Chretien P, O'Conor G, DeVita V, Thomas L. Radiotherapeutic implications of prospective staging in non-Hodgkin's lymphoma. Radiology 1974, 110: 655-7. PMID: 4811687, DOI: 10.1148/110.3.655.
RECENTLY RECOGNIZED COMPLICATIONS OF CANCER CHEMOTHERAPYArseneau J, Canellos G, DeVita V, Sherins R. RECENTLY RECOGNIZED COMPLICATIONS OF CANCER CHEMOTHERAPY. Annals Of The New York Academy Of Sciences 1974, 230: 481-488. PMID: 4595953, DOI: 10.1111/j.1749-6632.1974.tb14482.x.
Cyclical Combination Chemotherapy for Advanced Breast CarcinomaCanellos G, Devita V, Gold G, Chabner B, Schein P, Young R. Cyclical Combination Chemotherapy for Advanced Breast Carcinoma. The BMJ 1974, 1: 218. PMID: 4818162, PMCID: PMC1633086, DOI: 10.1136/bmj.1.5901.218.
Potential for Prolonged Disease-free Survival Following Combination Chemotherapy of Non-Hodgkin’s LymphomaSchein P, Chabner B, Canellos G, Young R, Berard C, DeVita V. Potential for Prolonged Disease-free Survival Following Combination Chemotherapy of Non-Hodgkin’s Lymphoma. Blood 1974, 43: 181-189. PMID: 4589318, DOI: 10.1182/blood.v43.2.181.181.
Streptozotocin for Malignant Insulinomas and Carcinoid Tumor: Report of Eight Cases and Review of the LiteratureSchein P, Kahn R, Gorden P, Wells S, DeVita V. Streptozotocin for Malignant Insulinomas and Carcinoid Tumor: Report of Eight Cases and Review of the Literature. JAMA Internal Medicine 1973, 132: 555-561. DOI: 10.1001/archinte.1973.03650100069013.
Hodgkin's Disease in ChildhoodYoung R, DeVita V, Johnson R. Hodgkin's Disease in Childhood. Blood 1973, 42: 163-174. PMID: 4793108, DOI: 10.1182/blood.v42.2.163.163.
MAINTENANCE CHEMOTHERAPY FOR ADVANCED HODGKIN'S DISEASE IN REMISSIONYoung R, Chabner B, Canellos G, Schein P, Devita V. MAINTENANCE CHEMOTHERAPY FOR ADVANCED HODGKIN'S DISEASE IN REMISSION. The Lancet 1973, 301: 1339-1343. PMID: 4122739, DOI: 10.1016/s0140-6736(73)91672-3.
The Use of Drugs in Combination for the Treatment of Cancer — Rationale and ResultsDeVita V, Schein P. The Use of Drugs in Combination for the Treatment of Cancer — Rationale and Results. New England Journal Of Medicine 1973, 288: 998-1006. PMID: 4348752, DOI: 10.1056/nejm197305102881905.
Intensive chemotherapy for Hodgkin's disease: long-term complications.DeVita V, Arseneau J, Sherins R, Canellos G, Young R. Intensive chemotherapy for Hodgkin's disease: long-term complications. National Cancer Institute Monograph 1973, 36: 447-54. PMID: 4744600.
Physiologic disposition of 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU) and 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (MeCCNU) in manSponzo R, Devita V, Oliverio V. Physiologic disposition of 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU) and 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (MeCCNU) in man. Cancer 1973, 31: 1154-1159. PMID: 4705152, DOI: 10.1002/1097-0142(197305)31:5<1154::aid-cncr2820310517>3.0.co;2-b.
Initial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu)Young R, Walker M, Canellos G, Schein P, Chabner B, Devita V. Initial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu). Cancer 1973, 31: 1164-1169. PMID: 4705154, DOI: 10.1002/1097-0142(197305)31:5<1164::aid-cncr2820310519>3.0.co;2-4.
Liver‐spleen scan in hodgkin's diseaseMilder M, Larson S, Bagley C, Devita V, Johnson R, Johnston G. Liver‐spleen scan in hodgkin's disease. Cancer 1973, 31: 826-834. PMID: 4706049, DOI: 10.1002/1097-0142(197304)31:4<826::aid-cncr2820310410>3.0.co;2-m.
Diagnosis of liver involvement by lymphoma: Results in 96 consecutive peritoneoscopiesBagley C, Thomas L, Johnson R, Chretien P, Devita V. Diagnosis of liver involvement by lymphoma: Results in 96 consecutive peritoneoscopies. Cancer 1973, 31: 840-847. PMID: 4267529, DOI: 10.1002/1097-0142(197304)31:4<840::aid-cncr2820310412>3.0.co;2-w.
Immune alterations in Hodgkin's disease. Effect of delayed hypersensitivity and lymphocyte transformation on course and survival.Young R, Corder M, Berard C, DeVita V. Immune alterations in Hodgkin's disease. Effect of delayed hypersensitivity and lymphocyte transformation on course and survival. JAMA Internal Medicine 1973, 131: 446-54. PMID: 4574227, DOI: 10.1001/archinte.131.3.446.
Immune Alterations in Hodgkin's Disease: Effect of Delayed Hypersensitivity and Lymphocyte Transformation on Course and SurvivalYoung R, Corder M, Berard C, DeVita V. Immune Alterations in Hodgkin's Disease: Effect of Delayed Hypersensitivity and Lymphocyte Transformation on Course and Survival. JAMA Internal Medicine 1973, 131: 446-454. DOI: 10.1001/archinte.1973.00320090136016.
Combination Chemotherapy and Survival in Advanced Hodgkin's DiseaseCanellos G, Young R, Berard C, DeVita V. Combination Chemotherapy and Survival in Advanced Hodgkin's Disease. JAMA Internal Medicine 1973, 131: 388-390. PMID: 4569375, DOI: 10.1001/archinte.1973.00320090078008.
Clinical pharmacology of cyclophosphamide.Bagley C, Bostick F, DeVita V. Clinical pharmacology of cyclophosphamide. Cancer Research 1973, 33: 226-33. PMID: 4688880.
High-dose intermittent intravenous infusion of procarbazine (NSC-77213).Chabner B, Sponzo R, Hubbard S, Canellos G, Young R, Schein P, Devita V. High-dose intermittent intravenous infusion of procarbazine (NSC-77213). Cancer Chemotherapy Reports 1973, 57: 361-3. PMID: 4584487.
Ovarian carcinoma metastatic to the diaphragm—frequently undiagnosed at laparotomy A preliminary reportBagley C, Young R, Schein P, Chabner B, Devita V. Ovarian carcinoma metastatic to the diaphragm—frequently undiagnosed at laparotomy A preliminary report. American Journal Of Obstetrics And Gynecology 1973, 116: 397-400. PMID: 4267636, DOI: 10.1016/s0002-9378(15)31299-0.
A decade of combination chemotherapy of advanced Hodgkin's diseaseDevita V, Canellos G, Moxley J. A decade of combination chemotherapy of advanced Hodgkin's disease. Cancer 1972, 30: 1495-1504. PMID: 4565815, DOI: 10.1002/1097-0142(197212)30:6<1495::aid-cncr2820300613>3.0.co;2-i.
Nonlymphomatous Malignant Tumors Complicating Hodgkin's Disease — Possible Association with Intensive TherapyArseneau J, Sponzo R, Levin D, Schnipper L, Bonner H, Young R, Canellos G, Johnson R, DeVita V. Nonlymphomatous Malignant Tumors Complicating Hodgkin's Disease — Possible Association with Intensive Therapy. New England Journal Of Medicine 1972, 287: 1119-1122. PMID: 5082192, DOI: 10.1056/nejm197211302872204.
THE EFFECT OF CHEMOTHERAPY ON THE GROWTH OF LEUKEMIA L1210 II. PERSISTENCE OF A NITROSOUREA‐INDUCED CHANGE IN THE GROWTH CHARACTERISTICS OF TRANSPLANT GENERATIONSDeVita V, Bray D, Bostick F, Bagley C. THE EFFECT OF CHEMOTHERAPY ON THE GROWTH OF LEUKEMIA L1210 II. PERSISTENCE OF A NITROSOUREA‐INDUCED CHANGE IN THE GROWTH CHARACTERISTICS OF TRANSPLANT GENERATIONS. Cell Proliferation 1972, 5: 459-466. PMID: 4654583, DOI: 10.1111/j.1365-2184.1972.tb00384.x.
Treatment of Ovarian Carcinoma: Possibilities for ProgressBagley C, Young R, Canellos G, DeVita V. Treatment of Ovarian Carcinoma: Possibilities for Progress. New England Journal Of Medicine 1972, 287: 856-862. PMID: 4561148, DOI: 10.1056/nejm197210262871705.
Clinical study with bleomycin: Tolerance to twice weekly dosageOhnuma T, Selawry O, Holland J, DeVita V, Shedd D, Hansen H, Muggia F. Clinical study with bleomycin: Tolerance to twice weekly dosage. Cancer 1972, 30: 914-922. PMID: 4116909, DOI: 10.1002/1097-0142(197210)30:4<914::aid-cncr2820300409>3.0.co;2-8.
An Increasing Awareness of Pneumocystis carinii PneumonitisRobbins J, DeVita V. An Increasing Awareness of Pneumocystis carinii Pneumonitis. The Annals Of Thoracic Surgery 1972, 14: 445-447. PMID: 4538515, DOI: 10.1016/s0003-4975(10)65252-6.
Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapyCanellos G, Young R, DeVita V. Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy. Clinical Pharmacology & Therapeutics 1972, 13: 750-754. PMID: 5053816, DOI: 10.1002/cpt1972135part1750.
Late Recurrence of Testicular TumorChabner B, Canellos G, Olweny C, DeVita V. Late Recurrence of Testicular Tumor. New England Journal Of Medicine 1972, 287: 413. PMID: 5065110, DOI: 10.1056/nejm197208242870817.
In vivo tumor cell kinetic studies: use of local thymidine injection followed by fine-needle aspiration.Muggia F, DeVita V. In vivo tumor cell kinetic studies: use of local thymidine injection followed by fine-needle aspiration. Translational Research 1972, 80: 297-301. PMID: 5044784.
Treatment of Hodgkin's Disease in Private PracticeDeVita V. Treatment of Hodgkin's Disease in Private Practice. JAMA 1972, 221: 298-299. PMID: 5067795, DOI: 10.1001/jama.1972.03200160048014.
Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously.Bagley C, Canellos G, Young R, Gallelli J, Devita V. Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously. Cancer Chemotherapy Reports 1972, 56: 387-91. PMID: 19051499.
Phytohemagglutinin-induced Lymphocyte Transformation: The Relationship to Prognosis of Hodgkin's DiseaseCorder M, Young R, Brown R, DeVita V. Phytohemagglutinin-induced Lymphocyte Transformation: The Relationship to Prognosis of Hodgkin's Disease. Blood 1972, 39: 595-601. PMID: 5022714, DOI: 10.1182/blood.v39.5.595.595.
Preliminary clinical trials of dichloromethotrexate (NSC-29630) in hepatocellular carcinoma.Vogel C, Adamson R, DeVita V, Johns D, Kyalwazi S. Preliminary clinical trials of dichloromethotrexate (NSC-29630) in hepatocellular carcinoma. Cancer Chemotherapy Reports 1972, 56: 249-58. PMID: 4339634.
Delayed hypersensitivity in Hodgkin's disease A study of 103 untreated patientsYoung R, Corder M, Haynes H, DeVita V. Delayed hypersensitivity in Hodgkin's disease A study of 103 untreated patients. The American Journal Of Medicine 1972, 52: 63-72. PMID: 5058359, DOI: 10.1016/0002-9343(72)90008-3.
Hematologic and Cytogenetic Remission of Blastic Transformation in Chronic Granulocytic LeukemiaCanellos G, DeVita V, Whang-Peng J, Carbone P. Hematologic and Cytogenetic Remission of Blastic Transformation in Chronic Granulocytic Leukemia. Blood 1971, 38: 671-679. PMID: 5288508, DOI: 10.1182/blood.v38.6.671.671.
Report of the Committee on Hodgkin's Disease Staging Procedures.Rosenberg S, Boiron M, DeVita V, Johnson R, Lee B, Ultmann J, Viamonte M. Report of the Committee on Hodgkin's Disease Staging Procedures. Cancer Research 1971, 31: 1862-3. PMID: 5121695.
Delayed Hypersensitivity in Patients with CancerCorder M, Young R, DeVita V. Delayed Hypersensitivity in Patients with Cancer. New England Journal Of Medicine 1971, 285: 522-524. PMID: 5558895, DOI: 10.1056/nejm197108262850917.
Treatment of Advanced Hodgkin's Disease with [1,3 Bis (2-Chloroethyl)-L-Nitrosourea] BCNUYoung R, DeVita V, Serpick A, Canellos G. Treatment of Advanced Hodgkin's Disease with [1,3 Bis (2-Chloroethyl)-L-Nitrosourea] BCNU. New England Journal Of Medicine 1971, 285: 475-479. PMID: 5558887, DOI: 10.1056/nejm197108262850902.
Anergy and tryptophan metabolism in Hodgkin’s diseaseDeVita V, Chabner B, Livingston D, Oliverio V. Anergy and tryptophan metabolism in Hodgkin’s disease. American Journal Of Clinical Nutrition 1971, 24: 835-840. PMID: 5091524, DOI: 10.1093/ajcn/24.7.835.
Effects of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) and its degradation products on progression of L1210 cells through the cell cycle.Bray D, DeVita V, Adamson R, Oliverio V. Effects of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) and its degradation products on progression of L1210 cells through the cell cycle. Cancer Chemotherapy Reports 1971, 55: 215-20. PMID: 5115843.
Hypercalcemia in chronic granulocytic leukemiaHaskell C, Devita V, Canellos G. Hypercalcemia in chronic granulocytic leukemia. Cancer 1971, 27: 872-880. PMID: 5280374, DOI: 10.1002/1097-0142(197104)27:4<872::aid-cncr2820270417>3.0.co;2-d.
Studies on the Anti-Tumor Action of Poly I: Poly CLevy H, Adamson R, Carbone P, DeVita V, Gazdar A, Rhim J, Weinstein A, Riley F. Studies on the Anti-Tumor Action of Poly I: Poly C. 1971, 55-65. DOI: 10.1007/978-3-642-85772-0_5.
Combination chemotherapy in the treatment of advanced Hodgkin's disease.Devita V, Serpick A, Carbone P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Annals Of Internal Medicine 1970, 73: 881-95. PMID: 5525541, DOI: 10.7326/0003-4819-73-6-881.
Combination Chemotherapy With Nitrogen Mustard, Vincristine, Procarbazine and Prednisone in Previously Treated Patients With Hodgkin's DiseaseLOWENBRAUN S, DEVITA V, SERPICK A. Combination Chemotherapy With Nitrogen Mustard, Vincristine, Procarbazine and Prednisone in Previously Treated Patients With Hodgkin's Disease. Blood 1970, 36: 704-717. PMID: 5488687, DOI: 10.1182/blood.v36.6.704.704.
CELL CYCLE CHARACTERISTICS OF HUMAN SOLID TUMORS IN VIVOYoung R, DeVita V. CELL CYCLE CHARACTERISTICS OF HUMAN SOLID TUMORS IN VIVO. Cell Proliferation 1970, 3: 285-290. PMID: 5523056, DOI: 10.1111/j.1365-2184.1970.tb00273.x.
Pentamidine: Clinical pharmacologic correlations in man and miceWaalkes T, Denham C, DeVita V. Pentamidine: Clinical pharmacologic correlations in man and mice. Clinical Pharmacology & Therapeutics 1970, 11: 505-512. PMID: 5310706, DOI: 10.1002/cpt1970114505.
Pyridoxine and Anergy in Hodgkin's DiseaseChabner P, DeVita V, Livingston D, Oliverio V. Pyridoxine and Anergy in Hodgkin's Disease. New England Journal Of Medicine 1970, 282: 1326. PMID: 5442374, DOI: 10.1056/nejm197006042822322.
The physiological disposition of the carcinostatic imidazole-4 (or 5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs.Vogel C, Denham C, Waalkes T, DeVita V. The physiological disposition of the carcinostatic imidazole-4 (or 5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs. Cancer Research 1970, 30: 1651-7. PMID: 5457935.
Combination chemotherapy with nitrogen mustard, vincristine, procarbazine, and prednisone in lymphosarcoma and reticulum cell sarcomaLowenbraun S, DeVita V, Serpick A. Combination chemotherapy with nitrogen mustard, vincristine, procarbazine, and prednisone in lymphosarcoma and reticulum cell sarcoma. Cancer 1970, 25: 1018-1025. PMID: 4910254, DOI: 10.1002/1097-0142(197005)25:5<1018::aid-cncr2820250505>3.0.co;2-a.
Abnormalities of Tryptophan Metabolism and Plasma Pyridoxal Phosphate in Hodgkin's DiseaseChabner B, DeVita V, Livingston D, Oliverio V. Abnormalities of Tryptophan Metabolism and Plasma Pyridoxal Phosphate in Hodgkin's Disease. New England Journal Of Medicine 1970, 282: 838-843. PMID: 5418547, DOI: 10.1056/nejm197004092821504.
Plasma Pyridoxal Phosphate Depletion by the Carcinostatic ProcarbazineChabner B, DeVita V, Considine N, Oliverio V. Plasma Pyridoxal Phosphate Depletion by the Carcinostatic Procarbazine. Experimental Biology And Medicine 1969, 132: 1119-1122. PMID: 5360989, DOI: 10.3181/00379727-132-34378.
Pneumocystis carinii Pneumonia — Successful Diagnosis and Treatment of Two Patients with Associated Malignant ProcessesDeVita V, Emmer M, Levine A, Jacobs B, Berard C. Pneumocystis carinii Pneumonia — Successful Diagnosis and Treatment of Two Patients with Associated Malignant Processes. New England Journal Of Medicine 1969, 280: 287-291. PMID: 5303991, DOI: 10.1056/nejm196902062800602.
Announcement of formation of: The lymphoma task force and pathology reference centerDevita V, Rappaport H, Frei E. Announcement of formation of: The lymphoma task force and pathology reference center. Cancer 1968, 22: 1087-1088. DOI: 10.1002/1097-0142(196811)22:6<1087::aid-cncr2820220602>3.0.co;2-b.
Heart in malignant lymphoma (Hodgkin's disease, lymphosarcoma, reticulum cell sarcoma and mycosis fungoides) A study of 196 autopsy cases∗Roberts W, Glancy D, Devita V. Heart in malignant lymphoma (Hodgkin's disease, lymphosarcoma, reticulum cell sarcoma and mycosis fungoides) A study of 196 autopsy cases∗. The American Journal Of Cardiology 1968, 22: 85-107. PMID: 4873149, DOI: 10.1016/0002-9149(68)90250-6.
Antitumor activity and some pharmacologic properties of anthramycin methyl ether.Adamson R, Hart L, DeVita V, Oliverio V. Antitumor activity and some pharmacologic properties of anthramycin methyl ether. Cancer Research 1968, 28: 343-7. PMID: 5641523.
The physiological disposition of the carcinostatic 1,3‐bis(2‐chloroethyU‐l‐nitrosourea (BCNU) in man and animalsDeVita V, Denham C, Davidson J, Oliverio V. The physiological disposition of the carcinostatic 1,3‐bis(2‐chloroethyU‐l‐nitrosourea (BCNU) in man and animals. Clinical Pharmacology & Therapeutics 1967, 8: 566-577. PMID: 4951973, DOI: 10.1002/cpt196784566.
Preliminary clinical studies with ibenzmethyzinDeVita V, Serpick A, Carbone P. Preliminary clinical studies with ibenzmethyzin. Clinical Pharmacology & Therapeutics 1966, 7: 542-546. PMID: 5939977, DOI: 10.1002/cpt196674542.
Pseudohyperkalemia Due to Release of Potassium from White Blood Cells during ClottingBronson W, DeVita V, Carbone P, Cotlove E. Pseudohyperkalemia Due to Release of Potassium from White Blood Cells during Clotting. New England Journal Of Medicine 1966, 274: 369-375. PMID: 5216594, DOI: 10.1056/nejm196602172740702.
SOME PHARMACOLOGIC PROPERTIES OF A NEW ANTITUMOR AGENT, N-ISOPROPYL-ALPHA-(2-METHYLHYDRAZINO)-P-TOLUAMIDE, HYDROCHLORIDE (NSC-77213).OLIVERIO V, DENHAM C, DEVITA V, KELLY M. SOME PHARMACOLOGIC PROPERTIES OF A NEW ANTITUMOR AGENT, N-ISOPROPYL-ALPHA-(2-METHYLHYDRAZINO)-P-TOLUAMIDE, HYDROCHLORIDE (NSC-77213). Cancer Chemotherapy Reports 1964, 42: 1-7. PMID: 14226125.

Edit Profile

Contact Information

Research & Publications

Biography

News

Coauthors

Selected Publications